Publications by authors named "Paul Schmidt-Barbo"

While T cell lymphomas are classified as mature neoplasms, emerging evidence indicates that malignant transformation may occur at an earlier stage of T cell maturation. In this study, we determined clonal architectures in a broad range of T cell lymphomas. Our multidimensional profiling indicates that a large part of these lymphomas in fact emerge from an immature lymphoid T cell precursor at a maturation stage prior to V(D)J rearrangement that undergoes branching evolution.

View Article and Find Full Text PDF
Article Synopsis
  • Inactivation of the A20 gene is linked to a specific form of lymphoma and is studied in patients with haploinsufficiency of A20 (HA20), revealing immune system impacts.
  • In a study of 34 HA20 patients, researchers found that the loss of one A20 gene copy leads to an increase in self-reactive lymphocyte receptors, often seen in lymphomas.
  • The immune changes are driven by a feedback loop involving tumor necrosis factor (TNF), A20, and NF-κB, and can potentially be reversed by anti-TNF treatment, but may still lead to lymphoma development.
View Article and Find Full Text PDF

The classification of B cell lymphomas-mainly based on light microscopy evaluation by a pathologist-requires many years of training. Since the B cell receptor (BCR) of the lymphoma clonotype and the microenvironmental immune architecture are important features discriminating different lymphoma subsets, we asked whether BCR repertoire next-generation sequencing (NGS) of lymphoma-infiltrated tissues in conjunction with machine learning algorithms could have diagnostic utility in the subclassification of these cancers. We trained a random forest and a linear classifier via logistic regression based on patterns of clonal distribution, VDJ gene usage and physico-chemical properties of the top-n most frequently represented clonotypes in the BCR repertoires of 620 paradigmatic lymphoma samples-nodular lymphocyte predominant B cell lymphoma (NLPBL), diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL)-alongside with 291 control samples.

View Article and Find Full Text PDF